Edition:
United Kingdom

Manas Mishra

AbbVie raises profit outlook on Botox recovery signs, new drugs growth

30 Oct 2020

Drugmaker AbbVie Inc raised its full-year profit forecast on Friday, bolstered by signs of recovery in demand for its Botox injection on easing COVID-19 restrictions and strong growth for its latest drugs, sending its shares up 6%.

Moderna on track to report late-stage COVID-19 vaccine data next month

29 Oct 2020

Moderna Inc on Thursday said it is on track to report early data from a late-stage trial of its experimental COVID-19 vaccine next month, offering the clearest timeline yet for when the world will know whether it is effective.

UPDATE 4-U.S. strikes deal with Lilly for potential COVID-19 antibody drug

28 Oct 2020

Oct 28 The U.S. government has agreed to pay $375 million to Eli Lilly and Co for 300,000 doses of its experimental COVID-19 antibody treatment, a drug similar to a treatment that U.S. President Donald Trump received.

Novavax delays U.S. trial of COVID-19 vaccine to November

27 Oct 2020

Novavax Inc on Tuesday delayed the start of a late-stage U.S. trial of its experimental coronavirus vaccine by roughly a month to the end of November, citing delays in scaling up the manufacturing process.

Pfizer says no COVID-19 vaccine data yet, could be week or more before it reports

27 Oct 2020

Drugmaker Pfizer Inc said on Tuesday it does not yet have data from the late-stage trial of the COVID-19 vaccine it is developing with Germany's BioNTech SE , and provided a timeline that makes its release unlikely ahead of the Nov. 3 U.S. presidential election.Pfizer said there had not yet been enough infections in the 44,000-volunteer trial to trigger an analysis of whether or not the vaccine works. An independent panel will conduct the first analysis when it reaches 32 infections.

Biogen readies for U.S. launch of Alzheimer's drug ahead of FDA meeting

21 Oct 2020

Biogen Inc said on Wednesday it was diverting part of its budget and resources for blockbuster multiple sclerosis drug Tecfidera towards a potential launch of its Alzheimer's disease drug, aducanumab.

UPDATE 3-Biogen readies for U.S. launch of Alzheimer's drug ahead of FDA meeting

21 Oct 2020

Oct 21 Biogen Inc said on Wednesday it was diverting part of its budget and resources for blockbuster multiple sclerosis drug Tecfidera towards a potential launch of its Alzheimer's disease drug, aducanumab.

Pfizer says earliest U.S. filing for COVID-19 vaccine would be late November

16 Oct 2020

Pfizer Inc said on Friday it could file in late November for U.S. authorization of the COVID-19 vaccine it is developing, suggesting that a vaccine could potentially be available in the United States by the end of the year. | Video

World News